Published in Science on April 15, 1983
Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science (2013) 1.62
The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med (2015) 1.33
Small molecule inhibitors of RORγt: targeting Th17 cells and other applications. Eur J Immunol (2012) 1.24
Role of the normal gut microbiota. World J Gastroenterol (2015) 1.12
Digitalis: where are we now? Br Heart J (1985) 1.11
Digoxin toxicity due to interaction of digoxin with erythromycin. BMJ (1989) 1.04
Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora. Gut (1989) 1.01
The intestinal metabolome: an intersection between microbiota and host. Gastroenterology (2014) 0.98
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol (2003) 0.97
Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest (2014) 0.95
Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res (2012) 0.95
Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium lentum. Appl Environ Microbiol (1986) 0.94
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol (2016) 0.93
Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes (2014) 0.89
Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids. Drug Metab Dispos (2015) 0.86
The functional impact of the intestinal microbiome on mucosal immunity and systemic autoimmunity. Curr Opin Rheumatol (2015) 0.86
RNA-Seq Quantification of Hepatic Drug Processing Genes in Germ-Free Mice. Drug Metab Dispos (2015) 0.85
Metagenomic surveys of gut microbiota. Genomics Proteomics Bioinformatics (2015) 0.81
Microbiome therapeutics - Advances and challenges. Adv Drug Deliv Rev (2016) 0.79
Xenobiotics: Interaction with the Intestinal Microflora. ILAR J (2015) 0.78
Personalized medicine in diabetes: the role of 'omics' and biomarkers. Diabet Med (2016) 0.78
Chemical transformation of xenobiotics by the human gut microbiota. Science (2017) 0.76
The meddling microbes midst our medicines. Gut Microbes (2013) 0.76
Mirror, mirror on the wall: which microbiomes will help heal them all? BMC Med (2016) 0.76
Reductive inactivation of digitoxin by Eubacterium lentum cultures. Appl Environ Microbiol (1987) 0.75
Clarithromycin induced digoxin toxicity. J Accid Emerg Med (1998) 0.75
The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome. Yale J Biol Med (2016) 0.75
Stimulation of 16-dehydroprogesterone and progesterone reductases of Eubacterium sp. strain 144 by hemin and hydrogen or pyruvate. Appl Environ Microbiol (1985) 0.75
The release of enzymes from Escherichia coli by osmotic shock and during the formation of spheroplasts. J Biol Chem (1965) 22.76
Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity. Antimicrob Agents Chemother (1974) 10.72
HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1979) 10.60
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother (1982) 10.08
Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds. Antimicrob Agents Chemother (1979) 10.01
Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases. Antimicrob Agents Chemother (1974) 9.66
Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1984) 8.62
beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin. Antimicrob Agents Chemother (1978) 8.28
Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin. Antimicrob Agents Chemother (1979) 7.65
Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother (1978) 7.39
The new beta-lactamase-stable cephalosporins. Ann Intern Med (1982) 7.20
Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. N Engl J Med (1969) 6.15
Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity. Antimicrob Agents Chemother (1978) 5.81
Purification and characterization of penicillinases from Salmonella typhimurium and Escherichia coli. Arch Biochem Biophys (1970) 5.39
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother (1983) 5.21
Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins. Antimicrob Agents Chemother (1978) 4.69
Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability. Antimicrob Agents Chemother (1982) 4.45
Azlocillin and mezlocillin: new ureido penicillins. Antimicrob Agents Chemother (1978) 4.28
Clavulanic acid, a novel inhibitor of beta-lactamases. Antimicrob Agents Chemother (1978) 4.27
Release of surface enzymes in Enterobacteriaceae by osmotic shock. J Bacteriol (1967) 4.05
In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother (1986) 3.98
Carbenicillin: clinical and laboratory experience with a parenterally administered penicillin for treatment of Pseudomonas infections. Ann Intern Med (1969) 3.62
On the surface localization of enzymes in E. coli. Biochem Biophys Res Commun (1964) 3.52
Relation of beta-lactamase activity and cellular location to resistance of Enterobacter to penicillins and cephalosporins. Antimicrob Agents Chemother (1972) 3.50
Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother (1981) 3.50
In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1984) 3.45
Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother (1984) 3.40
In vitro study of netilmicin compared with other aminoglycosides. Antimicrob Agents Chemother (1976) 3.35
Clinical spectrum and diagnosis of cobalamin deficiency. Blood (1990) 3.29
In vitro synergistic effect of netilmicin, a new aminoglycoside antibiotic. Antimicrob Agents Chemother (1976) 3.25
In vitro studies of tobramycin, an aminoglycoside antibiotic. Antimicrob Agents Chemother (1972) 3.23
Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin. Antimicrob Agents Chemother (1975) 3.17
Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother (1980) 3.14
High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc (1992) 3.12
Infective endocarditis--an evolving disease. A review of endocarditis at the Columbia-Presbyterian Medical Center, 1968-1973. Medicine (Baltimore) (1978) 3.03
In vitro activity of teichomycin compared with those of other antibiotics. Antimicrob Agents Chemother (1983) 3.00
Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med (1994) 2.98
Comparative inhibition beta-lactamases by novel beta-lactam compounds. Antimicrob Agents Chemother (1979) 2.97
Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) (1991) 2.77
The surface localization of penicillinases in Escherichia coli and Salmonella typhimurium. Biochem Biophys Res Commun (1968) 2.76
Antibiotic therapy of cholera. Bull World Health Organ (1967) 2.73
The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime. J Antibiot (Tokyo) (1979) 2.67
Variation in biologic availability of digoxin from four preparations. N Engl J Med (1971) 2.67
Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother (1979) 2.67
Infective endocarditis at the Presbyterian Hospital in New York City from 1938-1967. Am J Med (1971) 2.66
The 5'-nucleotidase of Escherichia coli. I. Purification and properties. J Biol Chem (1967) 2.59
Antibacterial activity of a monocyclic beta-lactam SQ 26,776. J Antimicrob Chemother (1981) 2.59
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA (1981) 2.55
Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother (1988) 2.52
Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med (1976) 2.49
Mecillinam, a novel penicillanic acid derivative with unusual activity against gram-negative bacteria. Antimicrob Agents Chemother (1976) 2.42
Cefaclor: in vitro spectrum of activity and beta-lactamase stability. Antimicrob Agents Chemother (1978) 2.42
Characterization of antibodies of high affinity and specificity for the digitalis glycoside digoxin. Biochemistry (1970) 2.39
Testing the physician's knowledge of antibiotic use: Self-assessment and learning via videotape. N Engl J Med (1975) 2.35
Septicemia with non-typhoid salmonella. Medicine (Baltimore) (1974) 2.31
Effective treatment of cobalamin deficiency with oral cobalamin. Blood (1998) 2.29
Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1982) 2.26
Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620. Antimicrob Agents Chemother (1986) 2.26
Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis (1996) 2.23
New macrolide antibiotics: azithromycin and clarithromycin. Ann Intern Med (1992) 2.22
Digoxin-specific antibodies. Proc Natl Acad Sci U S A (1967) 2.20
Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases. Am J Med (1985) 2.15
Bone and joint infections due to Salmonella. J Infect Dis (1978) 2.14
Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. Lancet (1986) 2.14
Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria. Am J Med (1987) 2.13
Antimicrobial resistance and R-factor transfer among isolates of Salmonella in the northeastern United States: a comparison of human and animal isolates. J Infect Dis (1975) 2.09
Direct detection and amplification of Helicobacter pylori ribosomal 16S gene segments from gastric endoscopic biopsies. Diagn Microbiol Infect Dis (1991) 2.06
Measurement of fibrinopeptide A in human blood. J Clin Invest (1974) 2.01
Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med (1981) 2.00
The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin Pharmacol Ther (1985) 1.99
Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr (1993) 1.98
The nephrotoxicity of antimicrobial agents (first of three parts). N Engl J Med (1977) 1.93
Rapid, reproducible enzyme immunoassay for gentamicin. J Clin Microbiol (1980) 1.92
In vitro studies of cephanone, a 3-heterocyclic-thiomethyl cephalosporin derivative. J Antibiot (Tokyo) (1973) 1.90
Oligonucleotide probe for detection and identification of Campylobacter pylori. J Clin Microbiol (1989) 1.90
Diagnosis of cobalamin deficiency I: usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Hematol (1990) 1.87
Antibacterial activity and beta-lactamase stability of temocillin. Antimicrob Agents Chemother (1982) 1.87
Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J (1993) 1.85
A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor. J Antibiot (Tokyo) (1978) 1.82
Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest (1988) 1.80
Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood (1993) 1.80
Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet (1995) 1.79
In vitro activity of sparfloxacin. Antimicrob Agents Chemother (1991) 1.79
The nephrotoxicity of antimicrobial agents (second of three parts). N Engl J Med (1977) 1.79
In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother (1986) 1.79
Status of laboratory testing in the diagnosis of megaloblastic anemia. Blood (1983) 1.79
Race, poverty, and survival in multiple myeloma. Cancer (1984) 1.78
Vitamin B12 deficiency is the primary cause of megaloblastic anaemia in Zimbabwe. Br J Haematol (1994) 1.78
In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents. J Antimicrob Chemother (1985) 1.78
Semisynthetic penicillin 6-(D(--)-alpha-carboxy-3-thienylacetamido) penicillanic acid active against Pseudomonas in vitro. Appl Microbiol (1971) 1.77
Pharmacokinetics of ticarcillin in patients with abnormal renal function. J Infect Dis (1976) 1.77
Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. J Infect Dis (1978) 1.75
In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem. Antimicrob Agents Chemother (1986) 1.74
Gentamicin in 1978. Ann Intern Med (1978) 1.73
In vitro activity of apalcillin compared with that of other new penicillins and anti-Pseudomonas cephalosporins. Antimicrob Agents Chemother (1982) 1.70
In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin. Antimicrob Agents Chemother (1983) 1.69